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Abstract 
Dysregulated protein degradative pathways are increasingly recognized as mediators of human 
disease. This mechanism may have particular relevance to desmosomal proteins that play critical 
structural roles in both tissue architecture and cell-cell communication as 
destabilization/breakdown of the desmosomal proteome is a hallmark of genetic-based 
desmosomal-targeted diseases, such as the cardiac disease, arrhythmogenic right ventricular 
dysplasia/cardiomyopathy (ARVD/C). However, no information exists on whether there are 
resident proteins that regulate desmosomal proteome homeostasis. Here we uncovered a cardiac 
COP9 desmosomal resident protein complex, composed of subunit 6 of the COP9 signalosome 
(CSN6), that enzymatically restricted neddylation and targeted desmosomal proteome 
degradation. CSN6 binding, localization, levels and function were impacted in hearts of classic 
mouse and human models of ARVD/C impacted by desmosomal loss and mutations, respectively. 
Loss of desmosomal proteome degradation control due to junctional reduction/loss of CSN6 and 
human desmosomal mutations destabilizing junctional CSN6 were also sufficient to trigger 
ARVD/C in mice. We identified a desmosomal resident regulatory complex that restricted 




The heart requires precise spatiotemporal control of cardiac protein turnover at distinct subcellular 
locations to maintain cardiac function as dysregulated protein degradative pathways are 
increasingly recognized as mediators of human cardiac disease (1-3). These pathways may have 
special relevance to desmosomal proteins, which play critical structural roles in both tissue 
architecture and cell-cell communication, especially in organs that undergo constant mechanical 
stress, such as the heart (4, 5).  
Five classic proteins encompass the cardiac desmosomal cell-cell junction protein complex, which 
we loosely term, “desmosomal proteome”, act to resist mechanical insult, which include 
desmoplakin (DSP), a central linker that tethers the tissue-specific desmosomal cadherins 
(desmoglein-2 (DSG2) and desmocollin-2 (DSC2)), to the intracellular intermediate filament 
cytoskeleton (desmin), through the intermediary armadillo proteins (plakoglobin (PKG) and 
plakophilin-2 (PKP2)) (4, 5). In the heart, the desmosomal complex acts alongside another 
mechanical junction, termed the fascia adherens junction (associated with actin cytoskeleton) as 
well as electrical channels, known as gap junctions to altogether synchronize muscle contraction 
(6). Genetic mutations in desmosomal genes, resulting in the destabilization/breakdown of the 
desmosomal proteome is a central hallmark of all genetic-based desmosomal-targeted diseases (4, 
7), including the cardiac disease, arrhythmogenic right ventricular dysplasia/cardiomyopathy 
(ARVD/C) (8, 9). Protein degradation is a critical part of protein quality control and mainly 
performed by two pathways which include the ubiquitin-proteasome system and autophagy-
lysosome pathway (3). These pathways recycle damaged, misfolded, or unneeded proteins into 
free amino acids for future use (3). The cardiac cell-cell junction is thought to display signs of 
active protein degradation as ubiquitin conjugates, autophagosomes and markers of ubiquitin-
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mediated selective autophagy have been localized to these locations in both healthy and diseased 
cardiomyocytes (10-14). However, no information exists on whether there are resident proteins 
that regulate desmosomal (cell junction) proteome homeostasis. 
Using an unbiased yeast-two-hybrid screen to search for desmosomal proteome regulators in the 
adult human heart, in combination with in silico molecular docking, in vivo genetic mouse and 
human heart tissue studies, we reveal protein degradation machinery that uniquely target the 
cardiac desmosome to regulate desmosomal proteome longevity and function. We identify 
constitutive photo-morphogenesis 9 signalosome subunit 6 (CSN6), a member of a pathway 
classically associated with protein quality control, as a resident desmosomal protein that 
endogenously restricts desmosome protein degradation to prevent the cardiac desmosomal targeted 







Identification of COP9 signalosome subunit 6 as a resident cardiac desmosomal protein. To 
identify proteins regulating cardiac desmosomal proteome homeostasis, we performed an unbiased 
yeast-two-hybrid screen using the human DSP N-terminus (1-519 amino acids) as bait and an adult 
human heart cDNA library as prey. DSP was selected as it is a central component in the 
desmosomal complex and the N-terminus was selected, as it is a major hub for interactions with 
desmosomal (armadillo) proteins (4) and “hotspot” for pathogenic ARVD/C mutations (15). We 
identified full-length constitutive photo-morphogenesis 9 signalosome subunit 6 (CSN6) as an 
interacting partner of DSP N-terminus in the adult human heart. Forced yeast-two-hybrid assays 
validated the interaction between DSP N-terminus and CSN6 (Figure 1A). In silico studies taking 
advantage of existing DSP and CSN6 crystal structures (16, 17) also showed that DSP and CSN6 
structurally interfaced as DSP N-terminus (amino acids 179-625) could structurally complex with 
the signature Mpr1, Pad1 N-terminal (MPN) domain of CSN6 (Figure 1B). In the adult mouse 
heart, endogenous CSN6 co-immunoprecipitated with endogenous DSP as well as the desmosomal 
armadillo protein, PKP2 (Figure 1C). Csn6 knockout (Csn6-iKO) heart extracts and IgG serum 
controls were used to demonstrate the specificity of CSN6 interactions to DSP and PKP2 (Figure 
1C). CSN6 is also expressed in insoluble (junctional-enriched) fractions and co-localized with 
DSP at the cardiac cell-cell junction in adult mouse hearts (Figure 1D and E). Cardiac-specific 
Dsp knockout hearts also displayed a striking reduction in CSN6 protein levels (insoluble fraction) 
and localization at the cardiac cell-cell junction (Figure 1D and E), highlighting CSN6 as an 
integral component of the cardiac desmosomal complex. 
Cardiac CSN6 loss selectively accelerates desmosomal protein degradation in vivo. The COP9 
signalosome (CSN), composed of eight subunits (CSN1-CSN8) is evolutionarily conserved in 
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eukaryotes and thought to have multi-faceted roles in controlling ubiquitin-mediated protein 
degradation as well as acting as a signaling docking hub (18-20). However, the biological role of 
CSN6 in the heart has remained unclear. To determine the role of CSN6 in the postnatal heart in 
vivo, we generated two cardiac-specific Csn6 knockout mice (Supplemental Figure 1A-C) by using 
cardiac-specific a-myosin-heavy chain (MHC)-Cre and cardiac-inducible a-MHC-MerCreMer 
mouse lines to assess its role in the early postnatal and adult heart, respectively (21, 22). Protein 
analyses revealed that CSN6 protein levels and junctional localization were lost in Csn6 knockout 
hearts (Supplemental Figure 1D-G). Given the direct protein interactions between CSN6 and DSP, 
we sought to assess the impact of CSN6 loss on the desmosomal proteome. CSN6 loss accelerated 
desmosomal protein complex destruction as Csn6 knockout hearts displayed selective loss of 
desmosomal protein levels when compared to controls (Figure  2). At early ages, mice harboring 
cardiac CSN6 loss resulted in primary loss of DSP as well as the gap junction (electrical) protein, 
connexin43 in mice (Figure 2A and C), which we have previously shown to be an early target of 
DSP loss (23). These early defects culminated into the total and specific destruction/loss of the 
desmosomal proteome at late ages in mice (Figure 2B and D). We further highlight that global 
effects on the cardiomyocyte were not observed as proteins residing in non-desmosomal (eg., 
fascia adherens junction and costamere/plasma membrane proteins) structures within 
cardiomyocytes were not significantly impacted in Csn6 knockout hearts (Figure 2B and D). RNA 
expression of desmosomal genes was also not impacted in Csn6 knockout hearts (Supplemental 
Figure 2), highlighting a post-transcriptional role for CSN6 within the desmosomal protein 
complex.  
CSN6 loss renders the cardiomyocyte susceptible to hyper-neddylation and targeted desmosomal 
protein degradation. Classic protein functions of CSNs are to enzymatically de-neddylate and 
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inactivate cullin RING E3 ubiquitin ligases (CURLs) to regulate ubiquitin-mediated protein 
degradation of targeted substrates (24). In vitro reconstitution assays refining the minimal CSN 
subunits required for de-neddylation activity defined that the CSN5-CSN6 heterodimer is 
sufficient and required to trigger de-neddylation activity (17, 25), thus, we also sought to assess 
CSN5 localization in the adult mouse heart in the absence and presence of CSN6. We reveal that 
CSN5 is also localized to the cardiac cell junction in adult mouse hearts, similar to CSN6 (Figure 
3A). Furthermore, we show that its cell junction localization was dependent on the presence of 
CSN6 as cardiac loss of CSN6 resulted in loss of CSN5 cell-cell junction localization and levels 
(Figure 3A), highlighting the presence of an active CSN subcomplex (consisting of CSN5 and 
CSN6) at the cardiac desmosome.  
We further showed that CSN6 loss directly impacted cullin neddylation mediated control as a 
select group of CURLs, namely cullin 1 and cullin 3 (migrate between 80-88 kDa) displayed a 
dramatic increase in their neddylated  (higher molecular weight) forms in CSN6 knockout hearts 
(Figure 3B and E). Immunofluorescence microscopy studies further revealed that CURLs that are 
directly impacted (hyperneddylated) by CSN6 loss (eg., cullin 3) are also localized to cell-cell 
junctions (Supplemental Figure 3). Consistent with these findings we observed a striking increase 
in neddylation (at the 80-88 kDa range) as well as ubiquitination, a downstream target of 
neddylation in Csn6 knockout hearts (Figure 3C, D, F and G). Cross-talk between ubiquitination 
and selective autophagy-mediated pathways was also evident as p62 levels were significantly 
upregulated in insoluble fractions of Csn6 knockout hearts (Figure 3D and G). These observations 
are consistent with restricted effects of CSN6 loss at the cell-cell junction as ultrastructural 
observations of hyper-accumulation of autophagic machinery was only observed at the cardiac 
cell-cell junction alongside destruction/loss of desmosomal structures (Figure 3H). Specifically, 
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Csn6 knockout hearts revealed early defects in desmosomal integrity, which included the hyper-
accumulation of autophagic vacuoles (red arrowheads) at remnants of destroyed electron dense 
desomosomes (eg., often observed as wider/half desmosomal structures (yellow arrowheads); 
Figure 3H). Csn6 knockout hearts also displayed hyper-accumulation of autophagic-like (multi-
layered) vesicles (green arrowhead) specifically at the cardiac cell junction (Figure 3H). The 
sufficiency of Csn6 loss (Cre group) to target increased neddylation and ensuing ubiquitination 
was also observed in cardiomyocytes (Figure 4A and D and Supplemental Figure 4A). Using 
cycloheximide chase assays, we show that CSN6 deficiency in cardiomyocytes results in a 
significant reduction in the half-life of key/core desmosomal proteins (which undergo more rapid 
degradation), demonstrating that protein degradation is specifically impacted in Csn6 deficient 
cardiomyocytes (Figure 4B and C). Restoration of CSN enzymatic function (via neddylation 
inhibitor MLN4924) and thus, targeting underlying deneddylation functions of CSN6 can also 
alleviate desmosomal protein loss caused by deletion of CSN6 (Figure 4D), highlighting 
desmosomal proteins as direct substrates of neddylation-mediated protein degradation. 
Disruption of the CSN6-desmosomal complex and protein degradation pathways underlies 
ARVD/C in mice and man. To determine the broad relevance of CSN6 pathways in desmosomal 
targeted diseases, we sought to assess CSN6 binding, localization, levels and function in classic 
mouse and human models of ARVD/C impacted by classic desmosomal loss/mutations. Hyper-
neddylation, hyper-ubiquitination and an increase in p62 levels was observed in hearts of cardiac-
specific Dsp knockout mice (Figure 5A and Supplemental Figure 4B), which harbored classic 
ARVD/C features (23) and a reduction in CSN6 localization at the cardiac cell-cell junction 
(Figure 1D and E). Furthermore, ultrastructural analyses revealed hyper-accumulation of 
autophagic machinery at the cardiac cell-cell junction alongside destruction/loss of desmosomal 
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structures (Figure 5B), similar to Csn6 knockout hearts (Figure 3H). To determine if CSN6 
pathways are disrupted in human ARVD/C, we identified a patient with a clinical diagnosis of 
ARVD/C that carried a previously identified desmoplakin (DSP) R315C missense mutation (26) 
and pathogenic PKP2 IVS10-1 G>C splice site mutation (27, 28). This patient provided a genetic 
platform to assess the importance of the CSN6-desmosomal interaction in human ARVD/C, as 
CSN6 can complex with both DSP and PKP2 (Figure 1C). The DSP R315C mutation was of 
interest as it is an evolutionarily conserved amino acid within the DSP N-terminus (Figure 5C), a 
region that could directly interact with CSN6 (Figure 1). In addition, the DSP R315C variant alone 
has been identified in patient populations harboring a sudden death syndrome (26), which parallels 
disease consequences of ARVD/C (sudden death). Analyses of the high resolution crystal structure 
of human DSP (N-terminal) plakin domain revealed that R315 is buried between the interface of 
two a-helices where its charged sidechain stabilizes these adjacent a-helices (Figure 5D). Using 
in silico predictions, we showed that DSP R315C destabilizes the DSP plakin domain, by breaking 
the electrostatic network of side chains that tether adjacent a-helices (Figure 5D), which in turn, 
we hypothesized lead to a disruption of the DSP-CSN6 interaction. Forced yeast two-hybrid assays 
revealed that the DSP R315C mutation abrogated the interaction between DSP and CSN6 (Figure 
5E), reinforcing in silico predictions and ability of this mutation to disrupt the DSP and CSN6 
interaction. Consistent with these findings, CSN6 localization was lost at the cardiac cell junction 
in human ARVD/C heart harboring these same desmosomal mutations (Figure 5F). To further 
reinforce that destabilization of the desmosomal-CSN6 complex underlies human ARVD/C, we 
showcase findings from five autopsied ARVD/C hearts harboring classic desmosomal mutations 
(DSP and PKP2), that highlight reduced junctional localization of CSN6 as a recurrent molecular 
alteration observed in human ARVD/C hearts (Figure 6). N-cadherin (marker of fascia adherens 
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junction) junctional localization was not impacted in human ARVD/C hearts when compared to 
controls (Figure 6), further validating the specificity and relevance of junctional CSN6 
dysregulation in human ARVD/C. 
Loss of desmosomal proteome degradation control due to CSN6 loss is sufficient to trigger the 
desmosomal-targeted disease, ARVD/C. Kaplan–Meier survival analyses revealed premature 
death of adult Csn6 knockout mice (Figure 7A and B).  At late survival curve time points, Csn6 
knockout mice displayed grossly enlarged and dilated cardiac chambers (Figure 7C and D). Adult 
Csn6 knockout mouse hearts also displayed extensive ventricular fibrosis and pronounced lipid 
deposition that was restricted to the myocardium and “triangle of dysplasia” (Figure 7E and F and 
Supplemental Figure 5A and B), reminiscent of pathological fibro-fatty infiltration found in human 
ARVD/C hearts (29).  We further revealed biventricular dilatation, dysfunction and failure in adult 
Csn6 knockout mouse hearts (Figure 7G and H and Supplemental Figure 5C), which is reminiscent 
of a biventricular form of human ARVD/C and given way to the recent adoption of the term 
arrhythmogenic cardiomyopathy to reference this class of diseases (30). At early survival curve 
time points, adult Csn6 knockout hearts displayed preserved cardiac dimensions and function 
(Supplemental Figure 5D). Instead, electrocardiography tracings revealed the presence of frequent 
premature ectopic beats/arrhythmias as well as ventricular depolarization delay in Csn6 knockout 
hearts (Figure 7I and J and Supplemental Figure 5E), reminiscent of early electrical defects found 
in human ARVD/C patients (8, 31). These data demonstrate the sufficiency of cardiac CSN6 loss 
to trigger classic electrical and structural features associated with human ARVD/C. 
Human desmosomal mutations destabilizing CSN6 are sufficient to trigger the desmosomal 
targeted disease, ARVD/C. To precisely validate and extrapolate how desmosomal (compound) 
mutations found in the human ARVD/C patient impact CSN6 interactions and functions in an 
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independent adult heart setting, we generated compound heterozygous mice harboring the same 
human desmosomal mutations (Double Het, Dsp R315C/+; Pkp2 IVS10-1 G>C/+; Supplemental 
6A-F). GST pull down assays exploiting GST-CSN6 and Double Het hearts extracts (for native 
DSP), highlighted the significant reduction of DSP binding to CSN6 in Double Het hearts (Figure 
8A and B). These molecular alterations lead to a significant reduction in junctional CSN6 and 
desmosomal protein levels, including DSP and PKP2, as well as downstream targets, such as 
connexin43 in right ventricular cell-cell junction extracts from Double Het hearts when compared 
to controls (Figure 8C and E). Proteins found in non-desmosomal compartments (eg., N-cadherin, 
marks fascia adherens junction) were not significantly impacted in Double Het mouse (Figure 8C 
and E), highlighting specificity of junctional targets impacted by CSN6 loss. An impact on protein 
degradation pathways consistent with loss of CSN6 function was observed in Double Het hearts  
as a significant increase in neddylation (at the 80-88 kDa range) was observed when compared to 
controls (Figure 8D and E). Using cycloheximide chase assays, we also showed a significant and 
progressive reduction in the half-life of key desmosomal proteins (triggering their rapid 
degradation) in neonatal Double Het cardiomyocytes (Supplemental Fig. 6G and H), highlighting 
an early (neonatal) and specific impact of reduced junctional localization of CSN6 on desmosomal 
protein degradation in Double Het hearts. Adult Double Het mice exhibited classic features 
associated with ARVD/C, which also recapitulated disease features found in Csn6 deficient mice. 
These included primary right ventricular defects (dilatation) (Figure 8F), in the absence of changes 
in left ventricular dimensions and function in Double Het hearts at an early age (Supplemental 
Figure 6I). Electrocardiography tracings also revealed the presence of frequent cardiac premature 
ectopic beats/arrhythmias in Double Het mice (Figure 8G). Electrical and functional deficits could 
be exacerbated with age in Double Het hearts as they exhibited evidence of recurrent baseline 
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arrhythmias associated with ventricular depolarization delay (QRS prolongation) as well as cardiac 
enlargement associated with left ventricular functional deficits (Figure 8H-K). Since we predicted 
that the Dsp R315C was sufficient on its own to destabilize interactions to CSN6, we also 
characterized single Dsp R315C homozygous mutant mice (Dsp Hom). GST pull down assays 
exploiting GST-CSN6 and Dsp Hom heart extracts (for native DSP), highlighted that these hearts 
now exhibited a complete abrogation in cardiac DSP binding to CSN6 (Supplemental Figure 7A). 
We show that deficits in these pathways were sufficient to trigger baseline electrical deficits 
(ventricular depolarization delay) and cardiac functional insufficiencies (reduced % fractional 
shortening) associated with ARVD/C in Dsp Hom mice (Supplemental Fig. 7B and D). Since 
exercise/catecholamines are known to exacerbate arrhythmias in ARVD/C (32, 33), we assessed 
arrhythmias in Dsp Hom mice in the context of isoproterenol (catecholamine) stress. We show that 
Dsp Hom mice exhibited a significant increase in catecholamine-induced arrhythmias when 
compared to controls (Supplemental Fig. 7C), further highlighting electrical deficits associated 
with ARVD/C. These data altogether highlight the importance of the DSP-CSN6 interaction (and 
their alterations in the context of classic human desmosomal mutations) as a trigger to the cardiac 




We provide evidence for the presence of an enzymatically active CSN subcomplex (containing 
core subunits CSN5 and CSN6) at the cardiac desmosome that targets its degradation. We show 
that CSN6 is an integral component of the cardiac desmosomal complex tethered by a direct 
interaction with the N-terminus of DSP. Taking advantage of DSP and CSN6 crystal structures 
(16, 17), our studies revealed the minimal DSP-CSN6 binding interface, which occurs between the 
spectrin repeats in the N-terminus of DSP and the MPN-domain of CSN6. The MPN domain of 
CSN6 is required for de-neddylation activity as studies utilizing a fragment of CSN6 deleted of 
the MPN domain resulted in a 100 fold decrease in de-neddylation activity of the CSN complex 
(17). Further refinement of the minimal CSN subunits required for de-neddylation activity has 
identified the sufficiency and requirement of the CSN5-CSN6 heterodimer to trigger de-
neddylation activity (17, 25). CSN5 is the only COP9 complex subunit that harbors enzymatic 
activity as a protease as its MPN domain contains an embedded JAB1 MPN domain 
metalloenzyme (JAMM) motif, which contains the required catalytic center to de-neddylate 
substrates (19, 34). We show that CSN5 is co-localized to cell junctions in the adult mouse heart, 
and its cell junction localization was dependent on the presence of CSN6, highlighting the presence 
of a minimal CSN subcomplex. In vitro studies have revealed that the CSN5-CSN6 heterodimer 
is sufficient to de-neddylate and facilitate cullin RING E3 ubiquitin ligase (CURLs) function (25), 
suggesting functional sufficiency of this minimal CSN subcomplex to enzymatically target 
substrates. Our studies highlight that CSN5-CSN6 likely heterodimerize at desmosomal junctions, 
but CSN5 may exclusively function to deneddylate CURLs and target desmosomal proteins for 
degradation. Future studies focused on disrupting the CSN5/6 heterodimer will be required to 
determine if CSN5 is also required for desmosomal substrate recognition.      
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The novelty of our studies lies in the identification of a desmosomal substrate recognition and 
protein turnover system imprinted within the desmosomal resident complex in the heart. The 
molecular architecture of the protein-protein interactions that define the desmosomal resident 
complex include desmosomal structural proteins, DSP (spectrin domain) and PKP2, which have a 
native affinity to the MPN domain of the core CSN member, CSN6 and thus, are recognized by 
neddylation-based protein degradation machinery. This concept is validated by our studies that 
show CSN6 interactions with desmosomal proteins, DSP and PKP2 in the adult mouse heart as 
well as the sufficiency of human desmosomal mutations in DSP and PKP2 to elicit 
reduction/abrogation of junctional localization of CSN6 in the adult mouse and human heart. 
CSN6’s known interactions (heterodimerization) with CSN5, act to form a subcomplex at the 
desomosomal cell-cell junction to de-neddylate/inactivate specific CURLs (eg., cullin 3) to prevent 
desmosomal protein ubiquitination and degradation. This concept is validated in Csn6 knockout 
hearts as they exhibit hyper-neddylated forms of select CURLs (cullins 1 and 3, which migrate at 
the 80-88 kDa range), further revealing CSN6 dependent cullins. We also show CURLs, such as 
cullin-3, are localized to cell-cell junctions, highlighting an epicenter in the cardiomyocyte that 
contains “enzymatically” functional COP9 machinery for de-neddylation activity. We speculate 
that CSN5’s enriched expression at the cell-cell junction may also be the reason why global effects 
of CSN6 loss are not observed in other compartments of the cardiomyocyte, despite CSN6 residing 
in areas outside of the desmosome. MLN4924 (neddylation inhibitor) studies highlight the 
essential role of CSN6 in deneddylation functions as MLN4924 could alleviate the desmosomal 
protein loss caused by deletion/loss of CSN6. The CSN complex has been hypothesized to form a 
“holocomplex” containing all eight CSNs as well as smaller subcomplexes with a subset of CSNs 
such as CSN1/2/3/8 and CSN4/5/6/7 (35, 36). Our studies highlight enrichment of a subset of CSN 
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subunits to the cell-cell junction, as previous studies in the field utilizing cardiac-specific Csn8 
knockout mice highlight the absence of CSN8 localization to the cell-cell junction (20, 37). Future 
studies focused on dissecting whether other CSN members associate or functionally impact the 
desmosomal resident complex, will be required to identify the CSN6 subcomplex members and 
dynamics restraining desmosomal protein degradation in cardiomyocytes. 
Our studies highlight that junctional reduction/loss of CSN6 is a central feature that drives derailed 
protein degradation and ARVD/C (diagnostic predictor of severity) in mice and man. We show 
using human myocardial tissue that reduced junctional localization of CSN6 is a molecular 
hallmark of ARVD/C associated with classic desmosomal mutations. We further show that  cardiac 
Csn6 knockout mice could recapitulate all classic disease features of ARVD/C. Central to these 
features is the loss of neddylation-mediated degradation control in Csn6 knockout hearts, which 
triggered hyper-accumulation of ubiquitin and selective autophagy protein degradation machinery 
at the cardiac desmosome to target its structural destruction. The interplay between neddylation 
and ubiquitination in Csn6 knockout hearts further highlight the sensitivity of the cardiomyocyte 
to stress associated with dysregulation of protein turnover pathways. Previous studies in 
cardiomyocytes showcase that disturbing the balance of COP9 function (by removing the complex 
subunit, CSN8) can in fact, lead to proteotoxicity (by overwhelming the ubiquitin proteasome 
system), which resulted in increased ubiquitination (20, 37). Our studies focused on deleting Csn6 
highlight similar consequences whereby cardiomyocyte CSN6 deficiency results in increased 
neddylation (increased CURL activity) in cell-cell junction fractions, leading to increases in 
ubiquitylation of substrate proteins that overwhelm the proteasome and autophagy system (eg., 
accumulation of autophagic structures) at this location, thus, resulting in increased/accumulation 
of ubiquitination. These results validate prior findings but give in addition, more mechanistic 
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insights into the interplay between neddylation and ubiquitination in cardiomyocytes. 
Interestingly, similar ultrastructural findings of accumulated protein degradation machinery at cell 
junctions has been reported in independent ARVD/C settings in mice and man (38, 39). 
Furthermore, we show that hearts from a classic ARVD/C mouse model (Dsp-cKO) displayed 
reduced junctional localization of CSN6 and similar protein degradation defects consistent with 
loss of CSN6 function. Finally we show the sufficiency of mice harboring human desmosomal 
mutations (Double Het, Dsp Hom) to destabilize junctional-associated CSN6 and trigger protein 
degradation defects (including triggering rapid desmosomal protein degradation) and cardiac 
disease (ARVD/C) features consistent with loss of CSN6 function. Interestingly, the rapid 
degradation of desmosomal proteins (reduced half-life of desmosomal proteins) observed in 
neonatal Double Het cardiomyocytes, further highlight the early disease consequences stemming 
from junctional reduction/loss of CSN6 in ARVD/C. Despite these findings, we cannot exclude 
the possibility that primary effects of desmosomal mutations contribute to ARVC disease causality 
in Double Het and Dsp Hom mice as opposed to CSN6 alone, given the complex nature of protein-
protein interactions in the desmosomal resident complex and signalosome. Future studies focused 
on dissecting the impact of CSN6 functional restoration in Double Het and Dsp Hom mice will be 
required to determine whether ARVC disease causality is solely attributed to CSN6 loss in these 
models. 
These studies set the stage to potentially reclassify desmosomal diseases, such as ARVD/C, as 
“diseases of desmosomal protein degradation” as well as provide mechanistic insights on new 
targets for  intervention (deneddylation) for ARVD/C, which can be exploited to restore the whole 
desmosomal proteome in a setting where desmosomal variants can no longer bind proteins that are 
required to maintain their structure (eg., CSN6). We also identify compartmentalized functions for 
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subunits of a classically large protein degradation signalosome complex, like COP9, as well as the 
structural interface (spectrin-MPN domain interaction) of how CSNs may target select substrates. 
Studies in desmosomal mutant mice (Double Het; Dsp Hom) further reveal that the heart 
dysfunction and arrhythmias associated with CSN6 reduction, precisely showcases how 
dysregulated CSN6 pathways are integral to the progressive electrical and structural phenotypes 
found in ARVD/C patients with classic desmosomal mutations. More specifically we also 
highlight the impact of the DSP R315C variant alone or in combination with other variants to 
predisposing the heart to ARVD/C disease susceptibility and progression. Thus, the strength of 
our data comes from the use of a multi-pronged approach which combines data from five different 
genetic mouse models (Dsp-cKO, Csn6-iKO, Csn6-cKO, Double Het, Dsp Hom mutant) and 
human cardiac biopsies (harboring 6 distinct desmosomal mutations) alongside in silico data, 
which intervene with the CSN6-DSP interaction (in multiple ways), to provide evidence for a novel 
role for CSN6 in the mechanistic and pathological underpinnings of human ARVD/C. 
The importance of maintaining desmosomal integrity is not only underscored in the human heart 
(resulting in ARVD/C) but also other organs such as kidney (resulting in polycystic kidney 
disease) and skin (resulting in palmoplantar keratodermas) as well as a variety of cancers (gastric, 
colorectal, prostate, bladder, breast, skin, head/neck, cervical, endometrial) and auto-immune 
diseases (pemphigus foliaceus & pemphigus vulgaris) (4, 7). We anticipate our findings have broad 
implications towards highlighting master regulatory mechanisms that are inherent to the 
desmosome, which may have implications in understanding drivers of other desmosomal-based 
diseases, such as cancers where desmosomal protein loss drives cancer metastasis progression (4). 
Since neddylation inhibitors are in phase 1 clinical trials to treat metastatic melanoma, acute 
myeloid leukemia and myelodysplastic syndromes (40, 41), our studies also provide new disease 
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indications and insights on sub-cellular targets of neddylation, which remain unclear in the field. 
Thus, our studies could also impact interpretations made from ongoing human clinical trials 
exploiting neddylation inhibitors as a therapeutic (40, 41).  
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Methods 
Yeast-two-hybrid assays. Yeast-two-hybrid screens and forced yeast-two-hybrid assays were 
performed using the Matchmaker® Gold Yeast Two-Hybrid System (Clontech). For the yeast-
two-hybrid screen, N-terminus DSP (1-519 amino acids) was cloned into pGBKT7 (bait plasmid) 
and transformed into the Y2HGold bait yeast strain (Clontech). Adult human heart cDNA library 
(Clontech Mate & Plate TM Library-Human Heart) served as prey and resided in a pGADT7 vector, 
which had been transformed into the Y187 yeast strain (Clontech). Mating and screening 
procedures were carried out as described by the manufacturer (Clontech). A very stringent cutoff 
for screening with fast growth on quadruple dropout plates was used for diploid yeast clones. After 
the screening, a total of 17 clones grew out. Colonies were further analyzed for active b-
galactosidase using an X-Gal filter lift assay. Plasmids from blue-positive clones were isolated and 
sequenced. Eleven different genes were identified using BLAST analysis and 1 (strongest 
interaction) out of  the 17 clones analyzed was CSN6. For forced yeast-2-hybrid assays, N-terminus 
DSP (WT or R315C) and PKP2 (WT) were cloned into pGBKT7 (bait plasmid) and transformed 
into Y2HGold yeast strain, while full-length CSN6 was cloned into pGADT7 (prey plasmid) and 
transformed into the Y187 yeast strain. Mating (pGBKT7 constructs with pGADT7 constructs) 
was carried out (Clontech) and interactions were assessed by b-galactosidase activity according to 
manufacturer’s instructions (Thermo Fisher). Negative controls (empty vector + CSN6; TD1 + 
CSN6) and positive (p53 + TD1) controls were used for b-galactosidase activity assays. 
Molecular docking and mutational analysis. Structure information for human DSP (amino acids 
179-625; RCSB PDB accession number: 3R6N) (16) and human COP9 subunit 6 (chain N in 
RCSB PDB accession number: 4D10) (17) was uploaded to ClusPro2.0 (https://cluspro.bu.edu/) 
for molecular in silico docking (42, 43). No restraints were put on the protein-protein docking 
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attempt. Resulting models should display a binding interface between the spectrin repeat 
encompassing R315 in DSP and the N-terminal MPN-domain in CSN6, as these were identified 
as minimal binding sites in our biochemical analyses. All models in the Van der Waals and 
electrostatic docking group matched these criteria. The model displaying the lowest energy score 
was further investigated (Figure 1B). For in silico modeling of the R315C mutation in DSP, 
structure minimization and calculation of energy changes (ΔΔG) was performed using YASARA 
and the FoldX module (44-46). The error margin of ΔΔG calculated by FoldX is approximately 
0.5 kcal/mol, indicating that changes in that range are insignificant. 
Experimental Animals. Cardiac-specific Dsp knockout have been previously generated and 
characterized (23). Csn6 genomic DNA was isolated from 129-SV/J mouse genomic DNA library 
(Stratagene). The Csn6 conditional targeting vector was designed to include loxP sites, 
surrounding pGKNeo cassette and exons 4-10 (Supplemental Figure 1A). G418-resistant 
embryonic stem cell (ES) clones were screened for homologous recombination by SpeI digestion, 
followed by Southern blot analysis, as previously described (47). A positive recombinant ES clone 
was microinjected into C57BL/6J blastocysts. Chimera mice were bred with C57BL/6J mice and 
crossed with Sox2-Cre mice (48) to selectively remove the pGKNeo cassette and generate Csn6 
floxed mice (Csn6 flox/flox).  Cardiac-specific Csn6 knockout mice (Csn6-cKO) were generated 
by crossing Csn6 flox/flox mice with a-myosin-heavy chain Cre (a-MHC-Cre) and cardiac 
inducible Csn6 knockout mice (Csn6-iKO) were generated by crossing Csn6 flox/flox mice with 
a-MHC-MerCreMer (Supplemental Figure 1B) (21, 22). Six-week old Csn6-iKO and littermate 
controls were injected with tamoxifen (50mg/kg per day) intraperitoneally once a day for five 
consecutive days (Supplemental Figure 1C).  
 
 21 
Mouse lines harboring heterozygous Dsp R315C mutation (Dsp R315C/+) and heterozygous Pkp2 
IVS10-1 G>C mutation (Pkp2 IVS10-1 G>C/+) were generated using CRISPR-Cas9 mediated 
methods that have been previously described (49). Briefly, CRISPR guide RNAs and single-strand 
oligodeoxynucleotide templates (ssODNs) were designed for Dsp R315C and Pkp2 IVS10-1 G>C 
mutations (Supplemental Table 1). CRISPR RNAs were chemically synthesized to contain the 
guide RNAs for Dsp R315C and Pkp2 IVS10-1 G>C mutations (Supplemental Table 1). For Dsp 
R315C mutant mice, a mixture of Dsp R315C cRNA, ssODNs, trans-activating crRNA and 
commercially Cas9 protein was injected into pronuclei of one-cell stage zygotes from C57BL/6J 
mice (The Jackson Laboratory). For Pkp2 IVS10-1 G>C mutant mice, a mixture of Pkp2 IVS10-1 
G>C cRNA, ssODNs, trans-activating crRNA and commercially Cas9 protein was injected into 
pronuclei of one-cell stage zygotes from C57BL/6J mice (The Jackson Laboratory). Genomic 
DNA was extracted from mouse tails and genomic fragments at target sites were amplified by PCR 
and sequencing. Genotype positive knockin mice were backcrossed with C57BL/6J mice (The 
Jackson Laboratory) for at least three generations to minimize for potential off-target effects. 
Double heterozygous (Dsp R315C/+; Pkp2 IVS10-1 G>C/+) mice were generated by crossing 
heterozygous Dsp R315C mutant mice with heterozygous Pkp2 IVS10-1 G>C mutant mice. Dsp 
R315C homozygous mutant mice were generated by crossing heterozygous Dsp R315C mutant 
mice.  
Co-immunoprecipitation assays. Endogenous co-immunoprecipitation assays were performed as 
previously described (47). Adult mouse heart lysates were incubated overnight at 4°C with Protein 
G beads (GE Healthcare), which were pre-incubated with rabbit anti-CSN6 antibody (Enzolife, 
Cat#BML-PW8295) or control rabbit IgG (Sigma, Cat#I5006). Bound proteins were eluted 
followed by SDS-PAGE and immunodetection of desmoplakin (mouse, 1:1000, Bio-Rad, 
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Cat#2722-5204), plakophilin-2 (mouse, 1:1000, Fitzgerald, Cat#10R-P130b) and CSN6 (1:500, 
Enzolife, Cat#BML-PW8295). 
Protein analysis. Total and insoluble (intercalated disc-enriched) protein extracts were isolated 
from cardiomyocytes and ventricles as previously described (23). Immunodetection of CSN6 
(Rabbit, 1:1000, Enzolife, Cat#BML-PW8295), desmoplakin (mouse, 1:1000, Bio-Rad, 
Cat#2722-5204), desmoglein-2 (mouse, 1:300, Fitzgerald, Cat#10R-D106a), desmocollin-2 
(rabbit, 1:500, Fitzgerald, Cat#20R-DR004), plakophilin-2 (mouse, 1:1000, Fitzgerald, Cat#10R-
P130b), plakoglobin (goat, 1:1000, Sigma, Cat#SAB2500802), b-catenin (mouse, 1:1000, Cell 
signaling, Cat#8480), N-cadherin (rabbit, 1:1000, Abcam, Cat# ab76057), connexin 43 (rabbit, 
1:1000, Invitrogen, Cat#71-0700), talin2 (mouse, 1:1000, Bio-Rad, Cat#MCA4771), vinculin 
(mouse, 1:1000, sigma, Cat#V9131), b1-integrin (rabbit, 1:1000, kind gift from R.S. Ross, 
University of California San Diego, La Jolla, CA, USA), NEDD8 (rabbit, 1:1000, Cell signaling, 
Cat#2745), ubiquitin (rabbit, 1:1000, Cell signaling, Cat#3933), p62 (guinea pig, 1:1000, Progen 
Biotechnik GMBH, Cat#71001), glyceraldehyde 3-phosphate dehydrogenase (mouse, 1:2000, 
Santa Cruz Biotechnology, Cat#sc32233), cullin1 (rabbit, 1:1000, sigma, Cat#C7117), cullin2 
(rabbit, 1:1000, Thermo Fisher, Cat#51-1800), cullin 3 (Mouse, 1:1000, Santa Cruz Biotechnology, 
Cat#sc-166053), cullin4A (rabbit, 1:1000, Sigma, Cat#SAB1411512), cullin4B (rabbit, 1:1000, 
Abgent, Cat#AP20232c), b-actin (Mouse, 1:1000, Santa Cruz Biotechnology, Cat#sc47778), GST 
(Mouse, 1:1000, Thermo Fisher, Cat#MA4-004) and a-tubulin (mouse, 1:2000, Sigma, 
Cat#T9028) was performed as previously described (23). 
Immunofluorescence microscopy. Heart cryosections were fixed in 100% acetone at -20ºC for 8 
minutes and were blocked in 10% goat serum/ phosphate-buffered saline (PBS) before incubation 
with antibodies. Human myocardial paraffin sections were deparaffinized, rehydrated and heated 
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for antigen retrieval as previously described (50, 51). Sections were subsequently stained with 
primary antibodies against CSN6 (Goat, 1:100, Santa Cruz Biotechnology, Cat#sc-47965 or 
Rabbit, 1:100, Enzolife, Cat#BML-PW8295), desmoplakin (mouse, 1:1000, Bio-Rad, Cat#2722-
5204), N-cadherin (rabbit, 1:100, Abcam, Cat#ab76057), CSN5 (rabbit, 1:100, cell signaling, 
Cat#6895S), plakoglobin (goat, 1:100, Sigma, Cat#SAB2500802), perilipin (rabbit, 1:100, Cell 
Signaling, Cat#3470S), cullin 3 (mouse, 1:100, Santa Cruz Biotechnology, Cat#sc-166053) and 
secondary antibodies (1:100, Jackson ImmunoResearch Inc.). Immuno-fluorescence images were 
acquired using confocal microscopy (Olympus FV1000 or Leica SP8). 
Electron microscopy. Cardiac ventricles were processed for electron microscopy and images were 
captured with FEI Tecnai Spirit G2 BioTWIN Transmission Electron Microscope as previously 
described (23).  
RNA isolation and real-time PCR analyses. Total RNA was isolated from hearts using TRIZOL 
(Invitrogen) according to the manufacturer’s instructions. The first-strand cDNA was generated 
using PrimeScript RT Reagent Kit with gDNA Eraser (Takara). Real-time PCR was performed on 
heart cDNA using primer sequences (Supplemental Table 2) diluted in Power SYBR Green PCR 
master mix (Applied Biosystems) and using a Bio-Rad Mastercycler. All values were normalized 
to 18S and GAPDH mRNA levels. 
Neonatal mouse ventricular cardiomyocyte isolation and treatments. Ventricular cardiomyocytes 
were isolated from neonatal (1–2 days old) mouse hearts and plated on laminin as previously 
described (23). Cardiomyocytes were subsequently infected with adenoviruses harboring lacZ 
(MOI 100) and Cre (MOI 100) for 24 hours and subsequently maintained in media consisting of 
DMEM, M199, 5% fetal bovine serum, 10% horse serum and 1% penicillin/streptomycin/ 
glutamine. For protein analyses, cardiomyocytes were collected at four days post-infection. For 
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cycloheximide (CHX) chase assays, Csn6 floxed cardiomyocytes were infected with adenoviruses 
harboring lacZ (MOI 100) and Cre (MOI 100) for 48 hours, and treated with CHX (10 µg/ml) for 
0, 8, 16, 24 and 32 hours and subjected to protein analysis. For cycloheximide chase assays in 
Double Het cardiomyocytes, neonatal mouse cardiomyocytes isolated from Double Het and WT 
mice were treated with CHX (10 µg/ml) for 0, 8, 16, 24, 36 and 48 hours and subjected to protein 
analysis. For MLN4924 treatment studies, cardiomyocytes were treated with 1µM MLN4924 or 
DMSO (vehicle) at 3 days post-infection and collected for protein analyses 6 hours later.  
Human myocardial tissues. Myocardial section was generated from a cardiac biopsy (formalin-
fixed, OCT embedded) from a patient harboring the DSP R315C and PKP2 IVS10-1 G>C mutation. 
This patient was referred to the Genetics of Cardiac Arrhythmia Program at University of 
California San Francisco and fulfilled revised clinical and diagnostic task force criteria for definite 
ARVD/C (52), upon comprehensive evaluation by cardiac magnetic resonance imaging, 
echocardiography, electrophysiology study and endomyocardial biopsy collection. Genetic testing 
on peripheral blood DNA was performed using a panel consisting of seven known ARVD/C genes 
(plakophilin-2, desmoplakin, desmoglein-2, desmocollin-2, plakoglobin, transmembrane protein 
43, and ryanodine receptor-2) and using next generation sequencing. Non-ARVD/C heart tissue in 
Figure 5F was obtained from an explanted unused cadaveric donor heart at the time of organ 
donation, as the donor was not eligible for heart transplantation and their death was not 
cardiovascular related (San Diego, CA, USA). Myocardial sections (formalin-fixed, paraffin 
embedded) designated with mutations DSP R1113X, DSP S1015fs1023X, DSP 1218+1G>A, 
PKP2 R413X and PKP2 V570fs576X were obtained from autopsied hearts from sudden deaths 
with diagnosis of ARVD/C with mutations identified in first degree relatives and confirmed with 
genetic material from the deceased, as previously described (50, 51).  
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Histological analysis. Mouse hearts were perfused in a relaxation buffer consisting of 300 mM 
KCl in PBS and fixed with 4% paraformaldehyde. Fixed hearts were embedded in OCT tissue tek 
(Sakura) or dehydrated and embedded in paraffin as previously described (23). Sections were cut 
between 5 and 10 µm thickness. Whole-heart (5 µM) paraffin sections were stained with 
hematoxylin and eosin (Sigma-Aldrich) and Masson’s trichrome (Sigma–Aldrich) stains 
according to the manufacturer’s instructions. Whole-heart (10 µM) cryosections were stained with 
Oil Red O (Sigma–Aldrich) according to the manufacturer’s instructions. Images were acquired 
with the Hamamatsu Nanozoomer 2.0 HT Slide Scanner. 
Magnetic resonance imaging (MRI). In vivo cardiac MRI was performed on a 7T horizontal bore 
MR scanner (Bruker). A quadrature volume coil (Bruker) was used for RF signal transmission and 
a two-channel surface array coil (RAPID MRI) was used for reception of the RF signal. Cardiac 
CINE images were acquired with an IntraGate (Bruker) retrospective gated 2D gradient echo pulse 
sequence (FLASH) with the following parameters: TE=3.1 ms, TR=5.6 ms, flip angle= 7º, 300-
400 repetitions and 20 frames. A field of view = 2.0 cm x 1.5 cm and data matrix =256 x 192 were 
prescribed for a spatial resolution = 0.078 mm/pixel. Equatorial frames containing the largest and 
smallest chamber diameters were selected to define the end-diastolic (ED) and end-systolic (ES) 
times, respectively. For MRI image analyses, two-dimensional (2D) endocardial contours were 
manually segmented for each heart at ED and ES (LV and RV) using image analysis software 
(Seg3D, NIH Center for Integrative Biomedical Computing). Contour areas were calculated with 
custom software in MATLAB, multiplied by the slice spacing and summed together to 
approximate calibrated end-diastolic volumes (EDV) and end-systolic volumes (ESV). Ejection 
fraction was defined as (EDV–ESV)/EDV x 100. 
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Echocardiography. Echocardiography was performed as previously described (47). Briefly, mice 
were anesthetized with 5% isoflurane for 15 seconds and maintained at 0.5% isoflurane during the 
procedure. VisualSonics, SonoSite FUJIFILM, Vevo 2100 ultrasound system with a linear 
transducer 32-56MHz (MS550S) was used to capture the images and videos. Measurements of 
heart rate, percentage fractional shortening (%FS) as well as left ventricular (LV) internal diameter 
at end-diastole (LVIDd) and end-systole (LVIDs) were determined from the M-mode tracing. 
Surface and Telemetry ECG. Surface ECG was performed as previously described (23). Briefly, 
mice were anesthetized with 5% isoflurane for 15 seconds and maintained at 1.5% isoflurane 
during the procedure. Six needle electrodes (30 gauge) were inserted subcutaneously into right 
forearm and left leg. For isoproterenol treatment studies, baseline surface ECG recordings were 
obtained in mice. Mice were subsequently injected intraperitoneally with isoproterenol (2.5 mg/kg 
body weight) and then re-evaluated for surface ECG at 10-15 minutes post-injection. For conscious 
telemetry studies, ECG transmitters (DSI) were subcutaneously inserted into the backs of mice as 
described previously (23). Positive and negative leads were fixed to the right shoulder muscle and 
the left leg muscle, respectively. ECG data was continuously acquired for 48h following 1 week 
after recovery from the implantation. ECG data was analyzed using LabChart. Quantification of 
ectopic beats within ECG tracings was calculated during a 5-minute interval every hour for a total 
of five hours.  
Protein expression and GST pulldown assay. GST pulldown assay was performed as previously 
described (53). Briefly, full length mouse Csn6 was cloned into the pGEX-6P-1 vector (GE Life 
Sciences). GST-CSN6 and GST proteins were expressed in E.coli BL21 cells (Invitrogen; Life 
Technologies) and purified using Glutathione Sepharose 4B (GE Life Sciences). Protein 
concentration was determined through densitometry of Coomassie stained SDS-page gels. Hearts 
 27 
were homogenized in lysis buffer (10mM Tris-HCl pH 8.0, 100 mM NaCl, 0.2% Nonidet P-40 
and 1X protease and phosphatase inhibitors, 1mM DTT). Heart extracts (500 µg per tube) were 
incubated with approximately 5µg of GST or GST-CSN6 proteins on a rotator overnight at 4°C. 
Beads were washed three times with lysis buffer, resuspended in SDS-sample buffer.  Bound 
proteins were analyzed through protein blot analyses. 
Statistics. Data are presented in text and figures as mean values ± standard error of the mean. The 
sample size was defined by R software. alpha was set to 0.05 and power was 90% for all studies. 
GraphPad Prism was used for analyses and significance was evaluated by Student’s two tailed t-
test and one-way or two-way ANOVA following Tukey or Sidak multiple pairwise comparisons 
tests. For Kaplan-Meier survival analysis, significance was assessed by the log-rank test. A p value 
of <0.05 was considered statistically significant. 
Study approval. All animal procedures were in full compliance with the guidelines approved by 
the University of California San Diego Animal Care and Use Committee. Procurement of 
ARVD/C human myocardial biopsy tissue was performed using standard procedures under 
protocols approved by institutional ethics review board at the University of California San 
Francisco (San Francisco, CA, USA). Consent for biopsy procedures and use of explanted tissues 
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Figure 1: Identification of CSN6 as a novel cardiac desmosomal interacting protein. (A) 
Quantitative b-galactosidase activity assays from forced yeast-2-hybrid studies. p53 with TD1 
served as positive control. Vector with CSN6 and TD1 with CSN6 served as negative controls. 
Data are mean ± s.e.m; one-way ANOVA with Tukey's multiple comparisons test, ***P<0.001. 
(B) In silico molecular docking of full-length CSN6 (Red) and DSP N-terminus (amino acids 179-
625, Blue) was performed using ClusPro. Resulting models displayed a binding interface between 
the spectrin repeat encompassing R315 in desmoplakin (DSP) and the N-terminal MPN-domain 
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in CSN6, as these were identified as minimal binding sites in our biochemical analyses. (C) CSN6 
was immunoprecipitated from control (Ctrl) and Csn6-inducible KO (iKO) mouse heart extracts 
at 10 weeks of age and subjected to protein blot analyses and quantification for DSP, plakophilin-
2 (PKP2) and CSN6 protein levels as indicated (n=4 per group). IgG serum was used as a control. 
Input refers to total protein prior to co-immunoprecipitation assay. Relative expression of input 
proteins were normalized to the loading control GAPDH. Data are mean ± s.e.m; two-way 
ANOVA with Sidak multiple comparison test,  **P<0.01, ***P<0.001. Molecular weight standards 
are indicated. (D) Protein blot analysis and quantification of CSN6 protein levels in insoluble heart 
extracts from Dsp-cKO and control mice (n=6 per group). The relative expression level of CSN6 
was normalized to the loading control a-tubulin. Data are mean ± s.e.m; Student’s two-tailed t-
test, ***P<0.001. Molecular weight standards are indicated. (E) Immunofluorescence staining of 
DSP (red), CSN6 (green) and N-cadherin (blue) in Dsp-cKO and control mouse heart sections 





Figure 2: Cardiac CSN6 loss accelerated desmosomal protein dissolution in vivo. (A and C) 
Protein blot analyses (A) and quantification of protein expression levels (C) in total protein 
extracts from Csn6-iKO and control hearts at 2 weeks post tamoxifen injection (n=5 per group). 
(B and D) Protein blot analyses (B) and quantification of protein expression levels (D) in total 
protein extracts from Csn6-iKO and control hearts at 6 weeks post tamoxifen injection (n=3 per 
group). FA: fascia adherens. GJ: gap junction. The expression levels of proteins were normalized 
to the loading control GAPDH. Data are mean ± s.e.m; two-way ANOVA with Sidak multiple 




Figure 3: Neddylation-mediated protein degradation is impacted by CSN6 loss. (A) 
Immunofluorescence staining of CSN subunits (CSN6 and CSN5, green) and cell-cell junctional 
marker (N-cadherin or PKG, red) in heart sections from Csn6-iKO and control mice at 2 weeks 
post tamoxifen injection (n=3 per group). Bar represents 20 µm. (B-D)  Protein blot analyses of 
cullin E3 ligases (B), NEDD8 (C), ubiquitin and p62 levels (D) in ventricular extracts from Csn6-
iKO and control mice at 6 weeks post tamoxifen injection (n=6 per group). (E-G) Quantification 
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of protein expression levels in (B-D), respectively. The expression levels of proteins were 
normalized to the loading control GAPDH or b-actin. Data are mean ± s.e.m; two-way ANOVA 
with Sidak multiple comparison test, ***P<0.001, ns, not significant. (H) Representative 
transmission electron micrographs from the right ventricle of Csn6-iKO and littermate control 
(n=4 per group). White arrows denote desmosome. Yellow arrows denote disorganized 
desmosome. Red arrowheads denote autophagic vacuoles. Green arrowheads denote multi-




Figure 4: CSN6-mediated protein degradation pathway targets desmosomal proteome 
degradation. (A) Protein blot analyses of Nedd8 and ubiquitin levels in Csn6 deficient (Cre, MOI 
100) and control (lacZ, MOI 100) ventricular cardiomyocytes. Experiments were repeated 
independently three times (2 wells per condition) with similar results. (B and C) Representative 
protein  blots (B) and quantification analyses (C) of desmosomal proteins in Csn6 deficient (Cre, 
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MOI 100) and control (lacZ, MOI 100) ventricular cardiomyocytes. After 48 hour infection, 
cardiomyocytes were treated with cycloheximide (CHX, 10 µg/ml) for 0, 8, 16, 24 and 32 hours. 
The expression levels of proteins were normalized to the loading control GAPDH. Data are mean 
± s.e.m; two-way ANOVA with Sidak multiple comparison test, *P<0.05, **P<0.01, ***P<0.001, 
ns, not significant. (D) Protein blot analyses and quantification of protein expression levels of cell-
cell junction proteins and NEDD8 levels in Csn6 deficient (Cre, MOI 100) and control (lacZ, MOI 
100) ventricular cardiomyocytes in the presence of vehicle or MLN4924 treatment. The expression 
levels of proteins were normalized to the loading control GAPDH. Data are mean ± s.e.m; two-
way ANOVA with Sidak multiple comparison test, *P<0.05, ***P<0.001, when compared to the 
control cardiomyocytes treated with DMSO (LacZ+DMSO). ###P<0.001, when compared to the 
Csn6 deficient cardiomyocytes treated with DMSO (Cre+DMSO). ns, not significant. Experiments 




Figure 5: Disruption of the CSN6-desmosomal complex and protein degradation pathways 
underlies ARVD/C in mice and man. (A) Protein blot analysis of NEDD8, ubiquitin and p62 
levels in ventricular extracts from Dsp-cKO and control mice at 8 weeks of age (n=5-6 per group). 
(B) Representative transmission electron micrographs from the right ventricle of Dsp-cKO and 
littermate control (n=4 per group). White arrows denote desmosome. Yellow arrows denote 
disorganized desmosome. Red arrowheads denote autophagic vacuoles. Green arrowheads denote 
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multi-membraned “autophagic-like” vesicles. Bar represents 500 nm. (C) DSP R315 region 
sequence alignment across vertebrate species. Red square denotes R315. (D) In silico molecular 
docking studies of DSP R315 (top) and R315C mutation (bottom). ∆∆G (change from R315 to 
R315C) is predicted with FoldX. ∆∆G > 0 = destabilizing and ∆∆G < 0= stabilizing. (E) β-
galactosidase activity from forced yeast-2-hybrid studies. p53 with TD1 served as a positive 
control. Vector with CSN6 and TD1 with CSN6 served as negative controls. Data are mean ± 
s.e.m; one-way ANOVA with Tukey's multiple comparisons test, ***P<0.001. Experiments were 
repeated independently three times with similar results. (F) Immunofluorescence staining of DSP 
(red) and CSN6 (green) in heart biopsies from an ARVD/C patient (harboring DSP R315C and 
PKP2 IVS10-1 G>C mutations) and non-ARVC control. White arrows denote cell-cell junction. 





Figure 6: Human desmosomal mutations associated with ARVD/C impact CSN6 localization. 
(A-G) Immunofluorescence staining of N-cadherin (red) and CSN6 (green) in ARVD/C heart 
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autopsies harboring DSP or PKP2 mutation and non-ARVD/C control. White arrows denote the 
cell-cell junctions which express both CSN6 and N-cadherin. Yellow arrowheads denote the cell-






Figure 7: Cardiac specific loss of CSN6 in mice results in sudden death and recapitulates key 
disease features of ARVD/C. (A and B) Kaplan–Meier survival curve analysis of Csn6-cKO and 
control (A, n=13) as well as Csn6-iKO and control (B, n=16) mice post tamoxifen injection (log-
rank test). (C) Heart weight to body weight ratios (HW/BW) from control and Csn6 deficient mice 
(n=6 per group). Data are mean ± s.e.m; two-way ANOVA with Sidak multiple comparison test). 
***P<0.001. (D) Representative whole heart sections from Csn6 deficient and control mice at 6 
weeks of age or post-tamoxifen injection (n=4 per group). Sections were stained for nuclei and 
cytoplasm with hematoxylin and eosin, respectively. Scale bar: 2mm. (E) Representative Masson’s 
trichrome stained cardiac sections from Csn6 deficient and control mice at 6 weeks of age or post-
tamoxifen injection (n=4 per group). Scale bar: 100µm. (F) Representative Oil Red O stained 
cardiac sections from Csn6-cKO and control mice at 6 weeks of age (n=4 per group). Scale bar: 
50µm. (G) Representative magnetic resonance images (short axis) from control and Csn6-iKO 
hearts at 6 weeks post-tamoxifen injection (n=5 per group). (H) MRI analyses of left and right 
ventricular ejection fractions (EF), end-diastolic volume (EDV) and end-systolic volume (ESV) in 
control and Csn6-iKO hearts at 6 weeks post-tamoxifen injection. Data are mean ± s.e.m; two-way 
ANOVA with Sidak multiple comparison test, **P<0.01, ***P<0.001. (I) Quantification of number 
of ectopic beats in Csn6-iKO and control mice (n=4 per group) at 2 weeks post-tamoxifen 
injection. Data are mean ± s.e.m; Student’s two-tailed t-test. *P<0.05. (J) Representative surface 
ECG tracings in Csn6-iKO and control mice at 2 weeks post-tamoxifen injection (n=10 per group). 
Quantification of heart rate (HR), PR and QRS intervals from ECG tracings was performed. Data 
from 100 ECG tracings per mouse were averaged for analysis. Data are mean ± s.e.m; Student’s 
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Supplemental Figure 1: Generation and validation of CSN6 loss in cardiac specific and 
cardiac inducible Csn6 knockout mice. (A) Restriction map of the relevant genomic region of 
Csn6, targeting construct, the mutated locus following recombination and Csn6 floxed allele (left). 
TK: thymidine kinase gene, Neo: neomycin resistance gene. Detection WT and mutant (target) 
alleles by southern blot analysis (right). (B) Schematic representation of breeding strategy to 
generate Csn6-cKO (Csn6 flox/flox; a-MHC-Cre(+)) and littermate control (Csn6 flox/flox; a-
MHC-Cre(-) or Csn6+/+; a-MHC-Cre(+)) mice. (C) Schematic representation of breeding strategy 
to generate Csn6-iKO (Csn6 flox/flox; a-MHC-MerCreMer(+)) and littermate control (Csn6 
flox/flox; a-MHC-MerCreMer(-) or Csn6 +/+; a-MHC-MerCreMer(+)) mice. To induce ablation 
of Csn6, 5- to 6-week-old mice were treated with daily intraperitoneal injection of tamoxifen 
(Sigma, 50µg/g per day) for 5 consecutive days. (D and E) Protein blot analysis of CSN6 in total 
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protein extracts from Csn6-cKO and control mice at 2 weeks of age (D) and Csn6-iKO mice at 2 
weeks post tamoxifen injection (E) (n=4 mice). GAPDH is used as a loading control. (F and G) 
Immunofluorescence staining of CSN6 (green) and N-cadherin (red) in cardiac sections from 
Csn6-cKO and control mice at 2 weeks of age (F) and Csn6-iKO at 2 weeks post tamoxifen 




Supplemental Figure 2: RNA levels of desmosomal genes are not impacted in Csn6 knockout 
hearts. Quantitative RT-PCR analysis of Csn6 and desmosomal gene expression in Csn6-iKO and 
control mouse hearts at 6 weeks post-tamoxifen injection (n=4 mice). 18S and Gapdh RNA were 
used as loading controls and showed similar results. Data are mean ± s.e.m; two-way ANOVA 





Supplemental Figure 3: Cullin 3 is localized to the cardiac cell-cell junction in adult WT and 
Csn6-iKO mouse hearts. Immunofluorescence staining of Cullin 3 (red), CSN6 (green) and N-
cadherin (magenta) in control and Csn6-iKO mouse hearts at 6 weeks post tamoxifen injection  




Supplemental Figure 4: Quantification of protein expression levels in Figure 4 and Figure 5. 
(A) Quantification of protein expression levels in Figure 4A. The expression levels of the proteins 
were normalized to the loading control GAPDH. Data are mean ± s.e.m; two-tailed Student’s t-
test. ***P<0.001. (B) Quantification of protein expression levels in Figure 5A. The expression 
levels of the proteins were normalized to the loading control GAPDH. Data are mean ± s.e.m;, 
two-way ANOVA with Sidak multiple comparison test, **P<0.01, ***P<0.001, ns, not significant.  
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Supplemental Figure 5: Characterization of cardiac specific Csn6 knockout mice. (A) 
Immunofluorescence staining of perilipin in triangular area of cardiac sections in Csn6-cKO and 
control mice at 6 weeks of age. Cardiac sections were counterstained with DAPI nuclear stain 
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(blue). Scale Bar: 100 µm. (B) Representative Oil Red O stained whole cardiac sections from 
Csn6-cKO and control mice at 6 weeks of age (n=4 per group). Scale bar: 2mm.(C) 
Echocardiographic M-mode analysis of heart function in Csn6 deficient and control mice at 6 
weeks of age and post-tamoxifen injection (n=6 mice). FS %: percent fractional shortening, 
LVIDd: left ventricular internal dimension at end-diastole. LVIDs: left ventricular internal 
dimension at end-systole. Data are mean ± s.e.m.; two-tailed Student’s t-test, *P<0.05; **P<0.01; 
***P<0.001; ns, not significant. (D) Echocardiographic M-mode analysis of heart function in Csn6-
iKO and control mice at 2 weeks post tamoxifen injection (n=4 mice).  Data are mean ± s.e.m.; 
two-tailed Student’s t-test, ns, not significant. (E) Representative conscious ECG tracings from 
Csn6-iKO (red) and control mice (black) at 2 weeks post tamoxifen injection (n=4 mice). Arrows 
denotes ectopic beats.  
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Supplemental Figure 6: Generation and characterization of knock-in mice harboring human 
equivalent DSP R315C and PKP2 IVS10-1 G>C mutations. (A and D) Schematic of the 
Cas9/sgRNA targeting site for the Dsp R327C (A) and Pkp2 IVS10-1 G>C (D) which are 
equivalent to the human R315C mutation and PKP2 IVS10-1 G>C respectively. The sgRNA 
coding sequence is underlined. The protospacer-adjacent motif (PAM) sequence is labeled in 
green. Uppercase: exon sequences. Lowercase: intron sequences. (B and E) Validation of Dsp 
R327C (B) and Pkp2 IVS10-1 G>C (E) allele by sequencing. (C and F) PCR using mutant-specific 
primers confirmed newborn mice contained the correct gene variant allele. (G and H) 
Representative protein  blots (G) and quantification analyses (H) of desmosomal proteins in 
ventricular cardiomyocytes which isolated from Double Het and WT pups. The cardiomyocytes 
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were treated with cycloheximide (CHX, 10 µg/ml) for 0, 8, 16, 24, 36 and 48 hours. The expression 
levels of proteins were normalized to the loading control GAPDH. Data are mean ± s.e.m; two-
way ANOVA with Sidak multiple comparison test, *P<0.05, **P<0.01. (I) Echocardiographic M-
mode analysis of left ventricular dimensions and function in Double Het and WT mice at 4 months 
of age (n=6 mice). FS %: percent fractional shortening, LVIDd: left ventricular internal dimension 
at end-diastole. LVIDs: left ventricular internal dimension at end-systole. Data are mean ± s.e.m.; 




Supplemental Figure 7: Characterization of Dsp R315C homozygous mice. (A) Protein blot 
analyses and quantification of protein expression levels following GST pulldown assay. GST 
(~25kDa) and GST-CSN6 (~60kDa) protein were incubated with the heart extracts from WT and 
Dsp R315C homozygous mice (Dsp Hom) at 1 year of age (n=4 per group). The expression levels 
of input proteins were normalized to the loading control GAPDH. Data are mean ± s.e.m; two-way 
ANOVA with Sidak multiple comparison test, *P<0.05, ***P<0.001. (B) Representative surface 
ECG tracings in Dsp R315C homozygous and WT mice at 1 year of age (n=8 per group). 
Quantification of heart rate (HR), PR and QRS intervals from ECG tracings was performed. Data 
from 100 ECG tracings per mouse were averaged for analysis. Data are mean ± s.e.m; Student’s 
two-tailed t-test, **P<0.01. QRS duration is indicated by the dotted line. (C) Quantification of 
number of  Dsp R315C homozygous and WT mice which displayed arrhythmia with 2.5mg/kg 
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isoproterenol treatment during ECG recording at 1 year of age (n=8 per group). Chi-square test, 
***P<0.05. (D) Echocardiographic M-mode analysis of left ventricular dimensions and function in 
Dsp R315C homozygous and WT mice at 1 year of age (n=8 per group). HR: heart rate; FS %: 
percent fractional shortening. Data are mean ± s.e.m.; Student’s two-tailed t-test. **P<0.01, no 
significant differences. 
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Supplemental Table 1: Dsp R315C and Pkp2 IVS10-1 G>C crRNA, trans-activating crRNA 
(tracrRNA), and single-strand oligodeoxynucleotides sequences used to generate knockin 
mice. 
 




















Supplemental Table 2: Primer sequences for real-time PCR analyses. 




























Figure 8: Human desmosomal mutations that destabilize CSN6 are sufficient to disrupt 
CSN6 expression, neddylation and trigger ARVD/C features in mice.  (A and B) Protein blot 
analyses (A) and quantification of protein expression levels (B) following GST pulldown assay.  
GST (~25kDa) and GST-CSN6 (~60kDa) protein were incubated with the heart extracts from WT 
and Double Het mice at 4 months of age (n=4 per group). The expression levels of input proteins 
were normalized to the loading control GAPDH. Data are mean ± s.e.m; two-way ANOVA with 
Sidak multiple comparison test, ***P<0.001, ns, not significant. (C-E) Protein blot analysis of 
cardiac cell-cell junction proteins (C),  NEDD8 expression levels (D) and  quantification of protein 
expression levels  (E) in right ventricular insoluble extracts from Double Het and WT mice at 4 
months of age (n=5 per group). The expression levels of proteins were normalized to the loading 
control b-actin. Data are mean ± s.e.m; two-way ANOVA with Sidak multiple comparison test, 
***P<0.001, ns, not significant. (F) Representative apical four chamber views from 
echocardiography ((n=6 per group) at 4 months of age. (G) Representative surface ECG tracing 
and quantification of premature ventricular contractions (PVCs) (n=4 per group) at 4 months of 
age. Data are mean ± s.e.m; Student’s two-tailed t-test. Arrows denote PVCs. *P<0.05. (H) 
Representative surface ECG tracings in Double Het and WT mice at 1 year of age (n=8-9 per 
group). Quantification of heart rate (HR), PR and QRS intervals from ECG tracings was 
performed. Data from 100 ECG tracings per mouse were averaged for analysis. Data are mean ± 
s.e.m; Student’s two-tailed t-test, **P<0.01. QRS duration is indicated by the dotted line. (I) 
Quantification of number of  Double Het and WT mice which displayed baseline arrhythmia 
during ECG recording at 1 year of age (n=8-9 per group). Chi-square test, *P<0.05. (J) Body 
weight (BW) and heart weight to body weight ratios (HW/BW) from Double Het and WT mice at 
1 year of age (n=8 per group). Data are mean ± s.e.m; Student’s two-tailed t-test. *P<0.05, ns, not 
significant. (K) Echocardiographic M-mode analysis of left ventricular dimensions and function 
in Double Het and WT mice at 1 year of age (n=8-10 per group). HR: heart rate; FS %: percent 
fractional shortening. Data are mean ± s.e.m.; Student’s two-tailed t-test. *P<0.05, no significant 
differences.  
 
 
 
 
